Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kerry, Brosnan"'
Autor:
Kerry Brosnan, Mark L. Chiu, Eva Emmell, Catherine N. Leettola, Sandra Santulli-Marotto, Olesya Chornoguz, Karen Leander
Publikováno v:
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 38:242-254
Although CD3 T cell redirecting antibodies have been successfully utilized for the treatment of hematological malignancies (blinatumomab), the T cell signaling pathways induced by these molecules are incompletely understood. To gain insight into the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::354d7333c3e0f8da28fb537d86bc0088
https://doi.org/10.1089/mab.2019.0035
https://doi.org/10.1089/mab.2019.0035
Autor:
Anthony A. Armstrong, Eva Emmell, Dennis R. Goulet, Songmao Zheng, Kerry Brosnan, Jose Pardinas, Jeffrey Luo, Susan H. Tam, Mark L. Chiu, Gary L. Gilliland, Adam Zwolak
Publikováno v:
mAbs
The increased number of bispecific antibodies (BsAb) under therapeutic development has resulted in a need for mouse surrogate BsAbs. Here, we describe a one-step method for generating highly pure mouse BsAbs suitable for in vitro and in vivo studies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c47706163315d2d22e8a3cacbaa31f
https://doi.org/10.1080/19420862.2017.1375639
https://doi.org/10.1080/19420862.2017.1375639
Autor:
Olesya, Chornoguz, Catherine N, Leettola, Karen, Leander, Kerry, Brosnan, Eva, Emmell, Mark L, Chiu, Sandra, Santulli-Marotto
Publikováno v:
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Although CD3 T cell redirecting antibodies have been successfully utilized for the treatment of hematological malignancies (blinatumomab), the T cell signaling pathways induced by these molecules are incompletely understood. To gain insight into the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0f22cbae11fe53c81f3a482b4e1a8ed4
https://pubmed.ncbi.nlm.nih.gov/31825302
https://pubmed.ncbi.nlm.nih.gov/31825302
Autor:
Dorie Capaldi, Daniel Weinstock, Patricia Rafferty, Mindi Walker, Kjell Johnson, Kerry Brosnan, Amy Volk, Devon D Sominski, Eva Emmell
Publikováno v:
Journal of Immunotoxicology. 13:226-234
An important component of safety assessment of new pharmaceuticals is evaluation of their potential to increase the risk of developing cancer in humans. The traditional 2-year rodent bioassay often is not feasible or scientifically applicable for eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61aebbf812ebf2a72e4f326b5b516b19
https://doi.org/10.3109/1547691x.2015.1045105
https://doi.org/10.3109/1547691x.2015.1045105
Autor:
Dorie Capaldi, Eva Emmell, Keri L. Soring, Jill Carton, Sharon Watson, Kerry Brosnan, Katharine D. Grugan, Allison R. Greenplate, Michelle Kinder, Randall J. Brezski, Theodore Petley, Robert Jordan
Publikováno v:
mAbs. 6:1265-1273
We report a chimeric monoclonal antibody (mAb) directed to a neo-epitope that is exposed in the IgG lower hinge following proteolytic cleavage. The mAb, designated 2095–2, displays specificity for IdeS-generated F(ab’)2 fragments, but not for ful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91b0967f17d400b056c1892f69e1d229
https://doi.org/10.4161/mabs.29825
https://doi.org/10.4161/mabs.29825
Autor:
Chichi Huang, Andrew Miller, Mindi Walker, Denise Chroscinski, Ram Achuthanandam, Thomas Nesspor, Peter J. Bugelski, Dorie Makropoulos, Kerry Brosnan, Justin Avery, Devon D. Egenolf, Krista Wilson
Publikováno v:
Current Pharmaceutical Biotechnology
CNTO 530 is an erythropoietin receptor agonist MIMETIBODYTM construct. CNTO 530 has been shown to be active in a number of rodent models of acquired anemia (e.g. renal insufficiency and chemotherapy induced anemia). We investigated the efficacy of CN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e6e0ddd4abbea364d75bbd218fbbb2c
https://doi.org/10.2174/1389201011314020015
https://doi.org/10.2174/1389201011314020015
Autor:
Jose Pardinas, Adam Zwolak, Kerry Brosnan, Anthony A. Armstrong, Eva Emmell, Tam Susan H, Dennis R. Goulet, Mark L. Chiu
Publikováno v:
Biophysical Journal. 110(3)
Validation of bispecific antibodies (BsAb), which greatly enhance the engagement of therapeutic targets, can require development of in vivo studies that often require mouse surrogate Abs. However, preparation of highly pure BsAb samples involves mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::386f295f8b8a7b9249fb6e5c42847381
Autor:
Kerry Brosnan, Dorie Makropoulos, Amy Volk, Mindi Walker, Peter J. Bugelski, Kay Meshaw, Patricia Rafferty, Jarrat Jordan, Devon D. Egenolf
Publikováno v:
Journal of Immunotoxicology. 9:43-55
Many immunosuppressive drugs are associated with an increased risk of neoplasia, principally non-melanoma skin cancers and B-cell lymphomas. However, only 6 of the 13 immunosuppressive drugs tested in 2 year bioassays increased the incidence of neopl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91c0b256e635625847863ea4da6736e
https://doi.org/10.3109/1547691x.2011.614646
https://doi.org/10.3109/1547691x.2011.614646
Autor:
Peter J. Bugelski, Dorie Makropoulos, Amy Volk, Laura Johns, Jarrat Jordan, Sharon Watson, Mindi Walker, Devon D. Egenolf, Karl Kavalkovich, Patricia Rafferty, Kerry Brosnan
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 63:236-249
Introduction Immunosuppressive drugs are associated with an increased risk of infections and in some cases neoplasia, particularly non-melanoma skin cancers. This paper describes the development of a model to test the effects of immunosuppressive dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b99a69cfa9df4fa6c76c4b1b1332b8f
https://doi.org/10.1016/j.vascn.2010.12.001
https://doi.org/10.1016/j.vascn.2010.12.001
Autor:
Peter J. Bugelski, Ram Achuthanandam, Laura Johns, Amy Volk, Dorie Makropoulos, Jin Lu, Kerry Brosnan, Wojciech Krzyzanski
Publikováno v:
Pharmacology & Pharmacy. :17-30
CNTO 530 and darbepoetin-a are long lived erythropoietin receptor agonists (ERAs). Clinically, anemia of chronic disease (ACD) is associated with increased expression of tumor necrosis factor-a (TNF-a) and mice transgenic for human TNF-a develop ACD.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::774aa6d95550e3581c8021ac535d7498
https://doi.org/10.4236/pp.2011.21003
https://doi.org/10.4236/pp.2011.21003